Asia-Pacific Cancer Vaccines Market - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)
Asia-Pacific Cancer Vaccines Market was worth $ 0.63 billion in 2018 and estimated to reach $ 1.46 billion by the end of 2023 with a growing potential of 18.24 %.
Asia-Pacific Cancer Vaccines Market was worth $ 0.63 billion in 2018 and estimated to reach $ 1.46 billion by the end of 2023 with a growing potential of 18.24 %.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Asia</strong>-<strong>Pacific</strong> <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong> was worth USD 0.63 billion in 2018 and estimated to reach<br />
USD 1.46 billion by the end of 2023 with a growing potential of 18.24 %. A cancer vaccine is a<br />
vaccine that either treats existing cancer or avoids advancement of cancer. <strong>Vaccines</strong> that treat<br />
existing cancer are known as therapeutic cancer vaccines. A number of the vaccines are<br />
"autologous", being made from tests taken from the patient, and are particular to that patient.<br />
A few analysts guarantee that cancerous cells routinely emerge and are pulverized by the<br />
immune system and that tumors form when the immune system neglects to kill them.<br />
A few sorts of cancer, for example, cervical cancer and some liver cancers, are caused by<br />
infections (oncoviruses). Customary vaccines against those infections, for example, HPV vaccine<br />
and hepatitis B vaccine, prevent those sorts of cancer. Different cancers are to some degree<br />
caused by bacterial infection(e.g. stomach cancer and Helicobacter pylori).<br />
One way to deal with cancer vaccination is to isolate proteins from cancer cells and vaccinate<br />
patients against those proteins as antigens, in the expectation of fortifying the immune system<br />
to slaughter the cancer cells. Research on cancer vaccines is in progress for the treatment of<br />
breast, lung, colon, skin, kidney, prostate and different cancers.<br />
Another approach is to produce an immune reaction in situ in the patient utilizing oncolytic<br />
viruses. This approach was utilized as a part of the medication talimogene laherparepvec, a<br />
variant of herpes simplex infection built to specifically duplicate in tumor tissue and to express<br />
the resistant stimulatory protein GM-CSF. This upgrades the anti-tumor safe reaction to tumor<br />
antigens discharged after viral lysis and gives a patient-specific vaccine.<br />
Get a comprehensive overview of the <strong>Asia</strong>-<strong>Pacific</strong> <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>:<br />
http://www.marketdataforecast.com/market-reports/asia-pacific-cancer-vaccines-market-<br />
1422/<br />
<strong>Asia</strong>-<strong>Pacific</strong> cancer vaccines market has driving factors like increasing number of people<br />
diagnosed with cancer, people getting aware of vaccines, smoking and excessive intake of<br />
alcohol, strong late-stage pipeline vaccines, vendor’s patient-assistance programs. Stringent<br />
regulations for getting approval, cost of vaccines are a few factors restraining the growth of this<br />
market.<br />
<strong>Asia</strong>-<strong>Pacific</strong> <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong>: Segmentation<br />
By <strong>Cancer</strong> Type<br />
<br />
<br />
<br />
<br />
<br />
Prostate<br />
Cervical<br />
Anal<br />
Throat<br />
Other cancers
Request a sample to stay up-to-date on the main trends affecting this<br />
market: http://www.marketdataforecast.com/market-reports/asia-pacific-cancer-vaccinesmarket-1422/request-sample<br />
By Vaccine Type<br />
<br />
<br />
<br />
<br />
<br />
Protein and Peptide based<br />
Tumour cell<br />
Dendritic cell<br />
Genetic vaccines<br />
Other <strong>Vaccines</strong><br />
By End Users<br />
<br />
<br />
<strong>Cancer</strong> Treatment Centres<br />
Research Institutes<br />
Major players influencing the <strong>Asia</strong>-<strong>Pacific</strong> cancer vaccines market are Dendreon,<br />
GlaxoSmithKline and Merck. Companies with their products in pipeline are Aduro Biotech,<br />
Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies,<br />
Bavarian<br />
Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine,<br />
GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio<br />
Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest<br />
Biotherapeutics, NovaRx,<br />
Transgene, Ubivac, Vaccinogen and Vaxon Biotech.<br />
About <strong>Market</strong> Data Forecast:<br />
OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio,<br />
<strong>Market</strong> Data Forecast is a firm working in the area of market research and business<br />
intelligence. With rich experience in research across various business domains, they cater to<br />
the needs of both individual and corporate clients. From all-encompassing umbrella markets<br />
to extremely specific niche markets covering all the major regions across the globe as part of<br />
the research scope, their research services offer one of a kind specialities with competitive<br />
pricing options. For more information, kindly visit, www.marketdataforecast.com.<br />
Contact:<br />
Abhishek Shukla<br />
Sales Manager (International Business Development)<br />
<strong>Market</strong> Data Forecast<br />
Direct Line: +1-888-702-9626<br />
Mobile: +91 998 555 0206<br />
Mail: abhishek@marketdataforecast.com
Change language